Sanofi buys Ablynx for $4.8 billion in biotech M&A boom
French drugmaker Sanofi has agreed to buy Belgian biotech company Ablynx for $4.8 billion, beating Novo Nordisk and marking its second big deal this month after buying Bioverativ.
Monday, January 29, 2018
Sanofi buys Ablynx for $4.8 billion in biotech M&A boom
Sanofi buys Ablynx for $4.8 billion in biotech M&A boom
French drugmaker Sanofi has agreed to buy Belgian biotech company Ablynx for $4.8 billion, beating Novo Nordisk and marking its second big deal this month after buying Bioverativ.
Related Posts:
Pandemic stirs Wall Street’s social conscience- NYSE to reopen trading floor after Memorial Day with changes
- Coronavirus likely hammered US retail sales again in April
- College campuses should aim for in-person instruction: Hoover Institute fellow
- Taiwan's TSMC to build Arizona chip plant as U.S.-China tech rivalry escalates
0 comments:
Post a Comment